A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.

被引：6
|
作者：
El-Rayes, Bassel F.
Shanda, Safi
Starodub, Alexander
O'Neil, Bert H.
Hanna, Wahid Tewfik
Shaib, Walid Labib
Oh, Cindy
Li, Wei
Li, Youzhi
Borodyansky, Laura
Li, Chiang
Bekaii-Saab, Tanios S.
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
[3] Indiana Univ, Hlth Goshen Ctr Canc Care, Bloomington, IN 47405 USA
[4] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[5] Univ Tennessee, Med Ctr, Knoxville, TN USA
[6] Boston Biomed Inc, Boston, MA USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supp1.4128
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4128
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Shanda, Safi
    Ciombor, Kristen Keon
    Noonan, Anne M.
    Hanna, Wahid Tewfik
    Sehdev, Amikar
    Shaib, Walid Labib
    Mikhail, Sameh
    Neki, Anterpreet S.
    Oh, Cindy
    Li, Youzhi
    Li, Wei
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Shahda, Safi
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Starodub, Alexander
    Hanna, Wahid Tewfik
    Borodyansky, Laura
    Oh, Cindy
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [3] A Phase Ib/II Study of Cancer Sternness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.
    Becerra, Carlos
    Braiteh, Fadi S.
    Spira, Alexander I.
    Langleben, Adrian
    Panasci, Lawrence C.
    Vukelja, Svetislava J.
    Hinshaw, Ioana M.
    Goodwin, Rachel Anne
    Panella, Timothy J.
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.
    Garcia, Agustin A.
    Hays, John L.
    Cote, Gregory Michael
    Becerra, Carlos
    Langleben, Adrian
    Lau, Susie K.
    Roman, Lynda D.
    McCormick, Colleen Catherine
    Richards, Donald A.
    Braiteh, Fadi S.
    Yimer, Habte Aragaw
    Richey, Stephen Lane
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
    Perez, Kimberly
    Chiarella, Anna M.
    Cleary, James M.
    Horick, Nora
    Weekes, Colin
    Abrams, Thomas
    Blaszkowsky, Lawrence
    Enzinger, Peter
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas
    Yurgelun, Matthew B.
    Goessling, Wolfram
    Giantonio, Bruce J.
    Brais, Lauren
    Germon, Victoria
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason R.
    Aguirre, Andrew J.
    Needle, Michael
    Rustgi, Anil K.
    Wolpin, Brian M.
    ONCOLOGIST, 2023, 28 (05): : 425 - 432
  • [6] CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Bekaii-Saab, Tanios S.
    Li, Chung-Pin
    Okusaka, Takuji
    O'Neil, Bert H.
    Reni, Michele
    Tabernero, Josep
    Qin, Shukui
    Van Cutsem, Eric
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
    Shan, Yan-Shen
    Li, Chung-Pin
    Khan, Gazala
    Lee, Woo Jin
    Choi, Hye Jin
    Chang, Heung-Moon
    Lee, Moon Hee
    Wallmark, John M.
    Chen, Pei-Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 648 - 648
  • [8] CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC)
    Bekaii-Saab, T.
    Goldstein, D.
    Li, C. P.
    Okusaka, T.
    O'Neil, B.
    Reni, M.
    Tabernero, J.
    Qin, S.
    Van Cutsem, E.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
    Becerra, Carlos
    Spira, Alexander I.
    Conkling, Paul R.
    Richey, Stephen Lane
    Hanna, Wahid Tewfik
    Cote, Gregory Michael
    Heist, Rebecca Suk
    Langleben, Adrian
    Laurie, Scott Andrew
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer
    Perez, Kimberly
    Weekes, Colin D.
    Cleary, James M.
    Abrams, Thomas Adam
    Blaszkowsky, Lawrence Scott
    Enzinger, Peter C.
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas Adam
    Yurgelun, Matthew B.
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason
    Aguirre, Andrew
    Needle, Michael N.
    Rustgi, Anil
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345